Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

Q02763 (TIE2_HUMAN) Homo sapiens (Human)

Angiopoietin-1 receptor UniProtKBInterProSTRINGInteractive Modelling

1124 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3)

Available Structures

16 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structural basis for angiopoietin-1 mediated signaling initiation Heteromer
Q15389;
23-536
Assess
Angiopoietin-2/Tie2 Complex Crystal Structure Heteromer
O15123;
23-445
NAG;NAG;CA;NAG;SO4;
Assess
Crystal structure of Tie2-agonistic antibody in complex with human Tie2 Fn2-3 Heteromer
541-735
22×EDO;
Assess
Crystal structure of the membrane proximal three fibronectin type III (FNIII) domains of Tie2 (Tie2…homo-2-mer442-735
Assess
Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2homo-2-mer443-735
NAG;NAG;NAG;NAG;
Assess
Homodimerization of Tie2 Fibronectin-like domains 2 and 3 in space group P21homo-2-mer542-734
NAG;NAG;NAG;
Assess
Tie2 Ligand-Binding Domain Crystal Structuremonomer23-445
NAG;NDG;SO4;
Assess
TIE2 KINASE DOMAINmonomer813-1121
Assess
Crystal structure of cytoplasmic kinase domain of Tie2 complexed with inhibitor CEP11207monomer814-1121
0CE;
Assess
CRYSTAL STRUCTURE OF TIE2 IN COMPLEX WITH DECIPERA COMPOUND DP1919monomer816-1122
SO4;919;
Assess
Structure of the Tie2 kinase domain in complex with a thiazolopyrimidine inhibitormonomer816-1120
QQ1;
Assess
Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 …monomer836-1117
RAJ;
Assess
Selection of fragments for kinase inhibitor design: decoration is keymonomer838-1117
3WR;
Assess
Evolution of a highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitormonomer838-1117
MR9;
Assess
Synthesis, Structural Analysis, and SAR Studies of Triazine Derivatives as Potent, Selective Tie-2 …monomer837-1116
MUH;
Assess
cFMS tyrosine kinase (tie2 KID) in complex with a pyrimidinopyridone inhibitormonomer917-935
SO4;IXH;
Assess

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
1fvr.1.Amonomer0.76813-1121
100.00
Assess
5utk.1.Amonomer0.73442-735
99.33
Assess
4k0v.1.Amonomer0.6423-536
99.81
Assess
3uto.2.Amonomer0.52638-1092
20.25
Assess

8 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22wqb.1.Amonomer0.74773-1077
QQ1;99.69
Assess
Isoform 25mya.1.Amonomer0.73400-692
100.00
Assess
Isoform 24k0v.1.Amonomer0.6223-493
99.37
Assess
Isoform 23uto.2.Amonomer0.52595-1048
20.56
Assess
Isoform 31fvr.1.Amonomer0.77665-973
100.00
Assess
Isoform 35utk.1.Amonomer0.75295-588
99.33
Assess
Isoform 34k0v.1.Amonomer0.589-389
96.90
Assess
Isoform 33uto.2.Amonomer0.53491-943
20.30
Assess